Stephanie Bauer

Advanced practice provider and family nurse practitioner with over 20 years of experience in hematology/oncology, specializing in transplant and cellular therapy. Proven ability to collaborate with key opinion leaders and multidisciplinary teams to translate complex clinical data into actionable practice. Manages a high-volume clinical practice, serving approximately 100 patients monthly, while overseeing inpatient and outpatient app teams.

• Family Nurse Practitioner (ANCC Board Certified)
• Good Clinical Practice (GCP) / CITI Certified
• Radiation Injury Treatment Network (RITN)
• NCI / RCR Registered

• National Marrow Donor Program/ Marrow Mates
• Blood Cancer United- Formally- Leukemia & Team member St. Louis Visnaries Campaign 2025
• Pedal for a Cause
• Quinlivan Foundation / Ben Polson Scholarship Board

• Co-Chair, APP Oncology Summit (APPOS), St. Louis, 2026
• Co-Chair, ASTCT PA/NP Conference, St. Louis, 2019
• Participate in advisory boards, round tables, speaker’s bureau and scientific engagement activities with industry partners (including: Incyte, JADPRO, Omeros, Jazz, Celgene, Sanofi/Genzyme, Pfizer, Kadmon, Autolus, Kite, Novartis, and Takeda)
• Active involvement in oncology education, mentorship, and professional development

• 2022, Abstract 610- ASTCT Annual Meeting 2022-Day Zero to Survivorship- Can Increased Monitoring throughout First Year of Transplant Impact Survivorship?, Poster presentation
• 2021, Management of adverse events associated with tyrosine kinase inhibitor use in adult patients with chronic myeloid leukemia in chronic phase: A nursing perspective., TBA J Adv Pract Oncol
• 2020, Bone Loss in Allogeneic Transplant Patients, Holly Comer MSN, ANP-BC1, Brooke Ramsey MSN, ANP-BC2, Katy Thomas ANP3, Stephanie Bauer MSN, FNP, BMT4, Oncology/ BMT, Barnes Jewish Hospital/ Washington University School of Medicine, St. Louis, MO, Oncology/BMT, Washington University School of Medicine, St. Louis, MO, Siteman Cancer Center, St. Louis, MO, Washington University School of Medicine, Saint Louis, MO
• 2016, Tyrosine Kinase Inhibitors for the Treatment of Chronic-Phase Chronic Myeloid Leukemia: Long-Term Patient Care and Management., J Adv Pract Oncol, 7, 42–54, 10.6004/jadpro.2016.7.1.3
• 2015, ASH Abstract #1938- Ruxolitinib as Sparing Agent for Steroid-Dependent Chronic Graft-Versus-Host Disease (cGVHD)., H. Jean Khoury1, Vamsi Kota, M.B;B.S2, Martha Arellano, MD1, Stephanie L Bauer, ANP3
• Anand P Jillella, MD1, Amelia Langston, MD1, Zaid Al-Kadhimi, MD4
• Zachariah DeFilipp, MD5, Audrey S Kim, RN2
• Elliott F. Winton, MD1, John F Dipersio, MD, PhD6
• 2015, Phase-1/-2 study of pomalidomide in chronic GvHD., Bone Marrow Transplant, 12/14/15, 10.1038/bmt.2015.298
• 2014, Conservative management of pneumatosis intestinalis after allogeneic hematopoietic SCT., P K Bhamidipati, a Ghobadi, S Bauer, J F DiPersio, I Pusic, Bone Marrow Transplantation, 49, 1436–1438
• 2013, Mescape Roundtable- The Nurse View: Common Clinical Challenges and Best Practices in Chronic CML., Sandra Allen-Bard, BSN, MSN, NPC, ANCC, AOCNP, Patricia S. Ault, FNP-BC, DNP, Stephanie Bauer, BSN, MSN, FNP, Mary Beth Rios, RN
• 2012, Interpreting Molecular Monitoring Results and International Standardization in Chronic Myleoid Leukemia., Journal of Advanced Practitioner in Oncology, 06/01/12, 3, 3
• 2009, Abstract: ASBMT Annual Meetings- Poster Presentation Sildenafil (Revatio) Therapy in Chronic Graft VS. Host: Improvement of Pulmonary CGVHD Symptoms
• 2009, Treatment of Chronic Myeloid Leukemia following Imatinib Resistance: a nursing guide to second-line treatment options., CJON, 10/01/09
• 2008, Abstract: ASBMT Annual Meetings Poster Presentation Sildenafil (Revatio) Therapy in Chronic Graft Vs. Host: Improvement of Pulmonary CGVHD Symptoms
• 2006, Abstract: ASH Annual Meetings # 108 Prolonged Engraftment and/or Primary Graft Failure Following Allogeneic Stem Cell Transplant in Patients treated with Dasatinib